# CRBU catalysts: Caribou Biosciences, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/crbu/catalysts

> Caribou Biosciences, Inc. (CRBU) has 1 upcoming catalyst. The next is the CB-011 trial start, late 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CRBU?

Caribou Biosciences, Inc. (CRBU) has 1 upcoming catalyst. The next is the CB-011 trial start, late 2027. Press release filed with the SEC (EX-99): "Caribou expects its cash, cash equivalents, and marketable securities will be sufficient to fund its current operating plan, including dose expansion for CB-011 and certain start-up activities for its planned vispa-cel pivotal trial, into 2H 2027." [Calendar and source filings](https://sec-api.dev/companies/crbu/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001619856-26-000007, https://www.sec.gov/Archives/edgar/data/1619856/000161985626000007/crbu-20260305xexx991.htm (retrieved 2026-11-12). Last confirmed 2026-08-13. Cite: https://sec-api.dev/companies/crbu/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Caribou Biosciences, Inc. |
| Ticker | CRBU (Nasdaq) |
| SEC CIK | 1619856 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/crbu |

## Cash runway

Cash $94.8M as of 2026-09-30; quarterly burn $22.5M; about 12.6 months of runway at that rate (XBRL company facts, accession 0001619856-26-000061).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 13, 2024 | [CB-012 trial start](https://sec-api.dev/pdufa/cb-012) | CRBU |  | completed | "The relevant time period commenced on February 13, 2024, when the first patient was dosed with CB-012 in our AMpLify phase 1 clinical trial, and would have ended upon the earlier of the third anniversary from the approval of our biologics license application ("BLA") by the FDA or 10 years from February 13, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm)) |
| March 10, 2025 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000014/crbu-20250310xexx991.htm)) |
| May 8, 2025 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000040/crbu-20250508xexx991.htm)) |
| 2H 2025 | [CB-011 interim data readout](https://sec-api.dev/pdufa/cb-011) | CRBU | r/r MM | scheduled | "On April 24, 2025, the Company also announced that it plans to present dose escalation data and share the recommended doses for expansion from the ongoing CaMMouflage phase 1 clinical trial of CB-011 in patients with r/r MM in the second half of 2025, including initial safety and efficacy data on a minimum of 25 patients at multiple dose levels using a deeper lymphodepletion regimen with at least three months of follow up." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000023/crbu-20250424.htm)) |
| 2H 2025 | [CB-010 trial start](https://sec-api.dev/pdufa/cb-010) | CRBU |  | scheduled | "Pending confirmation of our HLA matching strategy, we plan to initiate a pivotal Phase 3 trial for CB-010 in second-line large B cell lymphoma in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000006/crbu-20250113xexx991.htm)) |
| August 12, 2025 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000060/crbu-20250812xexx991.htm)) |
| late 2025 | [CB-011 trial start](https://sec-api.dev/pdufa/cb-011) | CRBU |  | scheduled | "The Company plans to initiate dose expansion of the CaMMouflage phase 1 clinical trial before the end of 2025 and to report dose expansion data, along with longer follow-up on dose escalation data, in 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000065/crbu-20251103.htm)) |
| November 12, 2025 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000070/crbu-20251112xexx991.htm)) |
| March 5, 2026 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000007/crbu-20260305xexx991.htm)) |
| May 7, 2026 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000035/crbu-20260507xexx991.htm)) |
| 2H 2026 | [CB-011 trial start](https://sec-api.dev/pdufa/cb-011) | CRBU | r/r MM | scheduled | "These forward-looking statements include, but are not limited to, any statements regarding the initiation, timing, progress, strategy, plans, objectives, expectations (including as to the results) with respect to the Company's CAR-T cell therapy product candidate clinical trials, including the expected design, protocol, and timing of initiation of the pivotal phase 3 clinical trial for vispa-cel in 2L LBCL CD19-naïve patients and its expectations regarding reporting initial dose expansion data and longer follow-up dose escalation data in the second half of 2026 from its ongoing CaMMouflage phase 1 clinical trial for CB-011 in patients with r/r MM" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000053/crbu-20260813xexx991.htm)) |
| August 13, 2026 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000053/crbu-20260813xexx991.htm)) |
| November 5, 2026 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000060/crbu-20261105xexx991.htm)) |
| late 2027 | [CB-011 trial start](https://sec-api.dev/pdufa/cb-011) | CRBU |  | scheduled | "Caribou expects its cash, cash equivalents, and marketable securities will be sufficient to fund its current operating plan, including dose expansion for CB-011 and certain start-up activities for its planned vispa-cel pivotal trial, into 2H 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000007/crbu-20260305xexx991.htm)) |

## Drugs

- [CB-010](https://sec-api.dev/pdufa/cb-010): 
- [CB-011](https://sec-api.dev/pdufa/cb-011): r/r mm
- [CB-012](https://sec-api.dev/pdufa/cb-012): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/crbu/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CRBU catalysts: Caribou Biosciences, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/crbu/catalysts

```bibtex
@misc{secapidev_companies_crbu_catalysts_20261116,
  title        = {CRBU catalysts: Caribou Biosciences, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/crbu/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_crbu_catalysts_20261116","title":"CRBU catalysts: Caribou Biosciences, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/crbu/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
